• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

激酶化学基因组集(KCGS):用于鉴定激酶易损性的开放科学资源。

The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification.

机构信息

Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

The Miami Project to Cure Paralysis, Peggy and Harold Katz Family Drug Discovery Center, Sylvester Comprehensive Cancer Center, and Departments of Neurological Surgery and Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA.

出版信息

Int J Mol Sci. 2021 Jan 8;22(2):566. doi: 10.3390/ijms22020566.

DOI:
10.3390/ijms22020566
PMID:33429995
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7826789/
Abstract

We describe the assembly and annotation of a chemogenomic set of protein kinase inhibitors as an open science resource for studying kinase biology. The set only includes inhibitors that show potent kinase inhibition and a narrow spectrum of activity when screened across a large panel of kinase biochemical assays. Currently, the set contains 187 inhibitors that cover 215 human kinases. The kinase chemogenomic set (KCGS), current Version 1.0, is the most highly annotated set of selective kinase inhibitors available to researchers for use in cell-based screens.

摘要

我们描述了一组化学基因组蛋白激酶抑制剂的组装和注释,将其作为研究激酶生物学的开放科学资源。该集合仅包括在大型激酶生化测定面板中筛选时显示出强大的激酶抑制作用和窄谱活性的抑制剂。目前,该集合包含 187 种抑制剂,涵盖 215 种人类激酶。激酶化学基因组集合(KCGS),当前版本 1.0,是研究人员在基于细胞的筛选中可使用的最具注释的选择性激酶抑制剂集合。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ebd/7826789/0988c4a3504b/ijms-22-00566-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ebd/7826789/e2b5fc1da8ab/ijms-22-00566-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ebd/7826789/053317152912/ijms-22-00566-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ebd/7826789/3a7e34716f55/ijms-22-00566-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ebd/7826789/9a5e4aab5083/ijms-22-00566-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ebd/7826789/f515bb60ffaf/ijms-22-00566-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ebd/7826789/0988c4a3504b/ijms-22-00566-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ebd/7826789/e2b5fc1da8ab/ijms-22-00566-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ebd/7826789/053317152912/ijms-22-00566-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ebd/7826789/3a7e34716f55/ijms-22-00566-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ebd/7826789/9a5e4aab5083/ijms-22-00566-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ebd/7826789/f515bb60ffaf/ijms-22-00566-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ebd/7826789/0988c4a3504b/ijms-22-00566-g006.jpg

相似文献

1
The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification.激酶化学基因组集(KCGS):用于鉴定激酶易损性的开放科学资源。
Int J Mol Sci. 2021 Jan 8;22(2):566. doi: 10.3390/ijms22020566.
2
Progress towards a public chemogenomic set for protein kinases and a call for contributions.蛋白质激酶公共化学基因组数据集的进展及征稿启事
PLoS One. 2017 Aug 2;12(8):e0181585. doi: 10.1371/journal.pone.0181585. eCollection 2017.
3
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.支持激酶信号研究和药物发现的化学基因组图谱的广泛活性屏幕。
Biochem J. 2013 Apr 15;451(2):313-28. doi: 10.1042/BJ20121418.
4
Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2).转化生长因子β激活激酶1(TAK1)和丝裂原活化蛋白激酶激酶激酶激酶2(MAP4K2)II型抑制剂的发现。
J Med Chem. 2015 Jan 8;58(1):183-96. doi: 10.1021/jm500480k. Epub 2014 Jul 30.
5
Predicting kinase inhibitors using bioactivity matrix derived informer sets.基于生物活性矩阵衍生的信息集预测激酶抑制剂。
PLoS Comput Biol. 2019 Aug 5;15(8):e1006813. doi: 10.1371/journal.pcbi.1006813. eCollection 2019 Aug.
6
PKIS deep dive yields a chemical starting point for dark kinases and a cell active BRSK2 inhibitor.蛋白激酶抑制剂研究深入揭示暗激酶的化学起点和具有细胞活性的 BRSK2 抑制剂。
Sci Rep. 2020 Sep 28;10(1):15826. doi: 10.1038/s41598-020-72869-9.
7
Chemogenomic Analysis of the Druggable Kinome and Its Application to Repositioning and Lead Identification Studies.基于药物基因组学的可用药激酶组分析及其在药物重定位和先导化合物鉴定研究中的应用。
Cell Chem Biol. 2019 Nov 21;26(11):1608-1622.e6. doi: 10.1016/j.chembiol.2019.08.007. Epub 2019 Sep 11.
8
Identification and further development of potent TBK1 inhibitors.强效TBK1抑制剂的鉴定与进一步开发。
ACS Chem Biol. 2015 Jan 16;10(1):289-98. doi: 10.1021/cb500908d.
9
Identification of Novel Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors by Kinase Activity-Based High-Throughput Screening for Anticancer Therapeutics.通过基于激酶活性的高通量筛选鉴定新型丙酮酸脱氢酶激酶 1(PDK1)抑制剂作为抗癌治疗药物。
ACS Comb Sci. 2018 Nov 12;20(11):660-671. doi: 10.1021/acscombsci.8b00104. Epub 2018 Oct 23.
10
Discovery of novel TAOK2 inhibitor scaffolds from high-throughput screening.通过高通量筛选发现新型TAOK2抑制剂支架
Bioorg Med Chem Lett. 2016 Aug 15;26(16):3923-7. doi: 10.1016/j.bmcl.2016.07.016. Epub 2016 Jul 6.

引用本文的文献

1
Kinome analysis of Madurella mycetomatis identified kinases in the cell wall integrity pathway as novel potential therapeutic drug targets in eumycetoma caused by Madurella mycetomatis.马杜拉足分支菌的激酶组分析确定了细胞壁完整性途径中的激酶是由马杜拉足分支菌引起的真菌性足菌肿新的潜在治疗药物靶点。
PLoS Negl Trop Dis. 2025 Sep 4;19(9):e0013482. doi: 10.1371/journal.pntd.0013482. eCollection 2025 Sep.
2
Drug Combinations Targeting FAK and MEK Overcomes Tumor Heterogeneity in Glioblastoma.靶向粘着斑激酶和丝裂原活化蛋白激酶激酶的药物组合克服了胶质母细胞瘤中的肿瘤异质性。
Pharmaceutics. 2025 Apr 23;17(5):549. doi: 10.3390/pharmaceutics17050549.
3

本文引用的文献

1
HighVia-A Flexible Live-Cell High-Content Screening Pipeline to Assess Cellular Toxicity.HighVia—一种灵活的活细胞高通量筛选管道,用于评估细胞毒性。
SLAS Discov. 2020 Aug;25(7):801-811. doi: 10.1177/2472555220923979. Epub 2020 May 27.
2
The multifaceted role of kinases in amyotrophic lateral sclerosis: genetic, pathological and therapeutic implications.激酶在肌萎缩侧索硬化症中的多方面作用:遗传学、病理学及治疗学意义
Brain. 2020 Jun 1;143(6):1651-1673. doi: 10.1093/brain/awaa022.
3
Regulation of Autophagy by mTOR Signaling Pathway.mTOR 信号通路对自噬的调控。
Chemoproteomic Profiling of for Characterization of Antifungal Kinase Inhibitors.
用于抗真菌激酶抑制剂表征的化学蛋白质组学分析
J Med Chem. 2025 Apr 10;68(7):7615-7629. doi: 10.1021/acs.jmedchem.5c00097. Epub 2025 Mar 20.
4
Chemogenomics for steroid hormone receptors (NR3).类固醇激素受体(NR3)的化学基因组学
Commun Chem. 2025 Feb 3;8(1):29. doi: 10.1038/s42004-025-01427-z.
5
Chemoproteomic Profiling of for Characterization of Anti-fungal Kinase Inhibitors.用于抗真菌激酶抑制剂表征的化学蛋白质组学分析
bioRxiv. 2025 Jan 10:2025.01.10.632200. doi: 10.1101/2025.01.10.632200.
6
Screening of a kinase inhibitor library identified novel targetable kinase pathways in triple-negative breast cancer.对激酶抑制剂文库进行筛选,确定了三阴性乳腺癌中可靶向的新型激酶途径。
Anticancer Drugs. 2025 Jan 1;36(1):39-48. doi: 10.1097/CAD.0000000000001658. Epub 2024 Aug 21.
7
Probe my Pathway (PmP): a portal to explore the chemical coverage of the human Reactome.探索我的通路(PmP):一个探索人类反应组化学覆盖范围的门户。
Database (Oxford). 2024 Dec 5;2024. doi: 10.1093/database/baae116.
8
Toward target 2035: EUbOPEN - a public-private partnership to enable & unlock biology in the open.迈向2035年目标:EUbOPEN——公私合作以在开放环境中推动和释放生物学潜能。
RSC Med Chem. 2024 Nov 29;16(2):457-464. doi: 10.1039/d4md00735b. eCollection 2025 Feb 19.
9
Milestones in chemoinformatics: global view of the field.化学信息学的里程碑:该领域的全球视野。
J Cheminform. 2024 Nov 5;16(1):124. doi: 10.1186/s13321-024-00922-0.
10
Chemogenomics for NR1 nuclear hormone receptors.化学生物基因组学与 NR1 核激素受体
Nat Commun. 2024 Jun 18;15(1):5201. doi: 10.1038/s41467-024-49493-6.
Adv Exp Med Biol. 2019;1206:67-83. doi: 10.1007/978-981-15-0602-4_3.
4
Dataset of the frequency patterns of publications annotated to human protein-coding genes, their protein products and genetic relevance.注释人类蛋白质编码基因、其蛋白质产物及遗传相关性的出版物频率模式数据集。
Data Brief. 2019 Jul 18;25:104284. doi: 10.1016/j.dib.2019.104284. eCollection 2019 Aug.
5
E2F1 proteolysis via SCF-cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition.通过 SCF-cyclin F 的 E2F1 蛋白水解作用,在 cyclin F 缺失和 Chk1 抑制之间产生合成致死性。
EMBO J. 2019 Oct 15;38(20):e101443. doi: 10.15252/embj.2018101443. Epub 2019 Aug 19.
6
Target 2035: probing the human proteome.目标 2035:探索人类蛋白质组。
Drug Discov Today. 2019 Nov;24(11):2111-2115. doi: 10.1016/j.drudis.2019.06.020. Epub 2019 Jul 3.
7
Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium.靶向帕金森病中的激酶:LRRK2、神经营养因子、艾塞那肽、尿酸、尼罗替尼和锂的共同机制。
J Neurol Sci. 2019 Jul 15;402:121-130. doi: 10.1016/j.jns.2019.05.016. Epub 2019 May 15.
8
Phenotypic Screening Combined with Machine Learning for Efficient Identification of Breast Cancer-Selective Therapeutic Targets.表型筛选与机器学习相结合,以有效鉴定乳腺癌选择性治疗靶点。
Cell Chem Biol. 2019 Jul 18;26(7):970-979.e4. doi: 10.1016/j.chembiol.2019.03.011. Epub 2019 May 2.
9
A Perspective on Extreme Open Science: Companies Sharing Compounds without Restriction.极端开放科学视角:公司无限制共享化合物。
SLAS Discov. 2019 Jun;24(5):505-514. doi: 10.1177/2472555219838210. Epub 2019 Apr 29.
10
Cheminformatics Tools for Analyzing and Designing Optimized Small-Molecule Collections and Libraries.用于分析和设计优化的小分子集合和库的 cheminformatics 工具。
Cell Chem Biol. 2019 May 16;26(5):765-777.e3. doi: 10.1016/j.chembiol.2019.02.018. Epub 2019 Apr 4.